AstraZeneca Results Presentation Deck
Rare Disease
Accelerating AstraZeneca's strategic and financial development
●
●
Strong financial
track record
Pre-acquisition: ~$6bn in
annual revenues¹
Best-in-class Ultomiris
conversion: Achieved >70%
in PNH, aHUS on track
●
●
Leader in
Complement
Science
Continued C5 inhibition
innovation with subcutaneous
Ultomiris and ALXN1720
Oral Factor D & subcutaneous
anti-properdin in development
●
29
1. FY2020, Alexion financial statements. PNH = paroxysmal nocturnal haemoglobinuria; aHUS = atypical haemolytic uraemic syndrome.
Diversified rare
disease pipeline
11 molecules in over 20
clinical trials
Portfolio of novel platform
technologies and medicines
Significant growth opportunity: >7,000 rare diseases known to exist,
only 5% have FDA approved medicinesView entire presentation